Reproxalap PDUFA Date (Aldeyra Therapeutics)
FDA PDUFA decision date for Reproxalap is March 16, 2026. Developed by Aldeyra Therapeutics. Indication: Dry eye disease. Current status: CRL.
Indication
Dry eye disease
Regulatory details
- Company: Aldeyra Therapeutics
- Therapeutic area: Ophthalmology
- Application type: NDA
- Review type: Standard
- PDUFA date: 2026-03-16
- Outcome: CRL